Nuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progress [Yahoo! Finance]
Nuvectis Pharma, Inc. (NVCT)
Company Research
Source: Yahoo! Finance
Research and Development Expenses : R&D expenses rose to $15.4 million, up by $2.2 million from the previous year. General and Administrative Expenses : G&A expenses increased to $7.5 million, a $1.5 million rise year-over-year. Cash Position : Cash and cash equivalents stood at $19.1 million as of December 31, 2023, slightly down from $20.0 million in the prior year. Interest Income : Interest income increased to $0.6 million, a $0.5 million improvement from FY 2022. Warning! GuruFocus has detected 1 Warning Sign with NVCT. On March 5, 2024, Nuvectis Pharma Inc ( NASDAQ:NVCT ) released its 8-K filing , detailing the company's financial results for the fiscal year 2023 and providing updates on its business operations. As a clinical-stage biopharmaceutical company, Nuvectis is dedicated to developing precision medicines for oncology, with a focus on addressing unmet medical needs. The company's net loss widened to $22.3 million for the year, compared to $19.1 million in th
Show less
Read more
Impact Snapshot
Event Time:
NVCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCT alerts
High impacting Nuvectis Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
NVCT
News
- Nuvectis Pharma: An Interesting Early Pipeline Does Not Justify A Buy [Seeking Alpha]Seeking Alpha
- Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference [Yahoo! Finance]Yahoo! Finance
- Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor ConferenceGlobeNewswire
- Nuvectis Pharma, Inc. (NASDAQ: NVCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
- Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
NVCT
Earnings
- 5/7/24 - Beat
NVCT
Analyst Actions
- 5/8/24 - HC Wainwright
NVCT
Sec Filings
- 5/15/24 - Form 4
- 5/13/24 - Form 4
- 5/13/24 - Form 4
- NVCT's page on the SEC website